Menopause: The Journal of The North American Menopause Society最新文献

{"title":"Pre-pandemic leukocyte count is associated with severity of post-acute sequelae of SARS-CoV-2 infection among older women in the Women's Health Initiative.","authors":"Ted K S Ng, Hind A Beydoun, Diane Von Ah, Aladdin H Shadyab, Shu Cheng Wong, Matthew Freiberg, Farha Ikramuddin, Patricia K Nguyen, Philippe Jean-Luc Gradidge, Lihong Qi, Zhao Chen, Keenan A Pituch, Suzi Hong, JoAnn E Manson","doi":"10.1097/GME.0000000000002490","DOIUrl":"https://doi.org/10.1097/GME.0000000000002490","url":null,"abstract":"<p><strong>Objective: </strong>Although dysregulated inflammation has been postulated as a biological mechanism associated with post-acute sequelae of severe acute respiratory coronavirus 2 (SARS-CoV-2) infection (PASC) and shown to be a correlate and an outcome of PASC, it is unclear whether inflammatory markers can prospectively predict PASC risk. We examined the association of leukocyte count and high-sensitivity C-reactive protein (hsCRP) concentrations, measured ~25 years prior to the coronavirus disease 2019 (COVID-19) pandemic, with PASC, PASC severity, and PASC-associated cognitive outcomes at follow-up among postmenopausal women.</p><p><strong>Methods: </strong>Using biomarker data from blood specimens collected during pre-pandemic enrollment (1993-1998) and data on 1,237 Women's Health Initiative participants who completed a COVID-19 survey between June 2021 and February 2022, we constructed multivariable regression models that controlled for pertinent characteristics. PASC status was defined according to established World Health Organization criteria.</p><p><strong>Results: </strong>Controlling for baseline characteristics, log e -transformed leukocyte count (β = 0.27; 95% confidence interval, 0.07-0.47, P = 0.009) and leukocyte count ≥5.5 × 1,000 cells/µL (β = 0.13; 95% confidence interval, 0.02-0.23; P = 0.02) were positively associated with PASC severity, defined as the sum of PASC symptoms, but not associated with overall PASC occurrence or PASC-related cognitive outcomes. Concentration of hsCRP, available on only ~27% of participants, was not associated with any of the PASC outcomes, controlling for the same covariates.</p><p><strong>Conclusions: </strong>Leukocyte count, a widely available clinical marker of systemic inflammation, is an independent predictor of PASC severity in postmenopausal women. Heightened inflammation preceding SARS-CoV-2 infection may contribute to PASC development. Limited statistical power to assess hsCRP role warrants further study.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the clinical, psychological, and social relevance of menopause for trans and gender diverse people: a qualitative study.","authors":"Michelle Qian Lin Xin, Riki Lane","doi":"10.1097/GME.0000000000002498","DOIUrl":"https://doi.org/10.1097/GME.0000000000002498","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to explore the meanings and experiences of menopause for trans and gender diverse (TGD) people and how menopause affects clinical practice.</p><p><strong>Methods: </strong>For this qualitative study in 2021-2022, a scoping literature review informed interview schedule development. Following email invitations, online semi-structured interviews were conducted in March-April 2021 in Australia with three prominent TGD community leaders (trans male, trans female, nonbinary person) and three experienced medical practitioners (general practitioner, endocrinologist, psychiatrist), which were audio-recorded and transcribed. Inductive, iterative thematic analysis of transcripts was conducted. A further literature search was completed in 2024.</p><p><strong>Results: </strong>Themes identified included the following: (1) no consensus on the definition of menopause for TGD individuals; (2) diverse menopause experiences existing in the TGD community; (3) large variations present regarding perimenopausal hormone therapy for older TGD patients: maintain dose, taper to low dose, or cease hormones; and (4) minimal support for TGD people to discuss menopause and concerns around aging. Saturation was not reached with the sample size.</p><p><strong>Conclusions: </strong>There is a paucity of relevant research and no consensus on definitions, management, or impacts of menopause for TGD people. Therefore, current management approaches should be individually tailored and guided by clinical expertise. To formulate practical and realistic recommendations for clinical practice, future research could include the following: (1) a broader literature review into varied gender-affirming hormone treatment (GAHT) regimens among aging TGD people; (2) utilizing the Delphi technique to achieve expert consensus regarding GAHT in older TGD individuals; and (3) a prospective study design of TGD participants on different GAHT regimens over time.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of Matricaria chamomilla intervention in managing menopausal symptoms: a triple-blind clinical trial.","authors":"Farideh Mohsenzadeh-Ledari, Mouloud Agajani Delavar, Ali Akbar Moghadamnia, Soraya Khafri, Reza Bekhradi, Fereshteh Behmanesh, Shahla Yazdani","doi":"10.1097/GME.0000000000002496","DOIUrl":"https://doi.org/10.1097/GME.0000000000002496","url":null,"abstract":"<p><strong>Objective: </strong>Menopausal symptoms can significantly impact women's quality of life. Herbal interventions like Matricaria chamomilla (chamomile) have been suggested as potential remedies. However, their efficacy and safety remain underexplored.</p><p><strong>Methods: </strong>This triple-blind clinical trial enrolled 80 postmenopausal women meeting specific criteria. Inclusion criteria included participants in early or late perimenopause, defined by a symptom score >15, FSH levels >40, or 2 years since menopause, with no significant comorbidities. Participants were randomly assigned to intervention and placebo groups. In a triple-blind clinical trial with 80 postmenopausal women (aged 47-62) from Babol City Health Center, participants were randomly assigned to receive either chamomile (100 mg capsules with 1.2% apigenin, four times daily) or a placebo over 12 weeks. Symptoms of menopause were assessed using the Australian Menopause Association's Scorecard Symptom Questionnaire. Over 12 weeks, they received either chamomile or placebo capsules, with side effect assessments every 4 weeks.</p><p><strong>Results: </strong>Notable differences were found between the intervention and control groups in the overall scores on the symptom scorecard from baseline to 12 weeks' postintervention (-10.36; 95% confidence interval [CI], -13.84 to -6.92; P < 0.001). Specific subscores also improved in the intervention group: vasomotor (-2.25; 95% CI, -3.09 to -1.42; P < 0.001), psychological (-3.74; 95% CI, -5.29 to -2.20; P < 0.001), locomotor (-2.70; 95% CI, -3.63 to -1.77; P < 0.001), and urological (-1.89; 95% CI, -2.77 to -1.00; P < 0.001). Both groups showed significant changes in total symptom scores over time (P < 0.001). Two participants experienced side effects, including mouth sores, skin spots, and itching, in the chamomile group, which led to their dropping out of the study.</p><p><strong>Conclusions: </strong>Chamomile intervention shows promise in alleviating menopausal symptoms, but its use warrants caution due to associated side effects. Further research is necessary to optimize dosage and mitigate adverse reactions for safer and more effective management of menopausal symptoms.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Traffic pollution, reproductive health, and depressive symptoms in a healthy multiethnic sample of reproductive age women in the Ovarian Aging Study.","authors":"Anwesha Pan, Martha Grace Cromeens, Marcelle I Cedars, Maria E Bleil","doi":"10.1097/GME.0000000000002483","DOIUrl":"https://doi.org/10.1097/GME.0000000000002483","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to determine whether exposure to traffic-related air pollution (TRAP) is associated with depressive symptoms while also characterizing the contribution of key explanatory factors related to sociodemographics and health. In addition, it aimed to also explore the role of reproductive health as a pathway through which exposure to TRAP may relate to depressive symptoms.</p><p><strong>Methods: </strong>Participants were 688 healthy reproductive-age women in the Ovarian Aging Study. TRAP was derived from distance-weighted traffic counts using residential addresses. Depressive symptoms were assessed by the Center for Epidemiological Studies Depression scale. Explanatory factors were assessed by interview and clinic measures, including demographics (age, race/ethnicity), socioeconomic status (SES) (individual SES, neighborhood SES), general health (smoking, body mass index), and reproductive health (menarcheal age, contraceptive use, parity, menstrual cycle characteristics).</p><p><strong>Results: </strong>In cross-sectional, step-wise multivariate regression analyses, greater exposure to TRAP was related to more depressive symptoms (b = 0.779, P = 0.015). Lower individual SES, longer menstrual cycle length, and experiencing change (vs no change) in menstrual cycle length were also related to more depressive symptoms (P's < 0.05). Examination of each model step showed that variance in depressive symptoms was attributable to TRAP (1.2%, P = 0.004), demographics (1.0%, P = 0.217), SES (1.4%, P = 0.007), general health (0.3%, P = 0.356), and reproductive health (2.0%, P = 0.015). Finally, menstrual cycle length, a marker of reproductive health status, partially mediated effects of TRAP on depressive symptoms (indirect effect: b = 0.064, P = 0.020).</p><p><strong>Conclusions: </strong>Findings showed that exposure to TRAP is associated with depression, along with SES and reproductive health factors, and that reproductive health may be a pathway through which TRAP relates to depression.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between hormone therapy and glioma risk in US women: a cancer screening trial.","authors":"Jinyu Pan, Chuan Shao, Chao Xu, Gang Zhang, Haotian Jiang, Tao Tang, Hui Tang, Nan Wu","doi":"10.1097/GME.0000000000002507","DOIUrl":"https://doi.org/10.1097/GME.0000000000002507","url":null,"abstract":"<p><strong>Objective: </strong>Gliomas are the most common primary brain tumors in adults, and the role of hormone therapy (HT) in their development remains controversial. This study with a cohort design aimed to investigate the association between HT use and glioma risk using the data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.</p><p><strong>Methods: </strong>We analyzed data from 75,335 women, aged 50-78, who were enrolled between 1993 and 2001. The median follow-up period was 11.82 years. Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the relationship between HT use and glioma risk, adjusting for various potential confounders.</p><p><strong>Results: </strong>Over the follow-up period, 101 participants were diagnosed with glioma. After adjusting for relevant variables, there was no significant association between HT use and glioma risk (HR, 1.16; 95% CI, 0.75-1.81). Similarly, no significant associations were found when considering HT status or duration of use. However, in subgroup analysis by education, marital status, body mass index, oral contraceptive, hysterectomy, ovariectomy, ever been pregnant, age at menarche, and age at menopause, we found that a significant positive association was only observed in the group with at least college graduate (HR, 3.00; 95% CI, 1.02-8.84). The interaction effect for education was not significant (P = 0.056).</p><p><strong>Conclusions: </strong>Our findings suggest no overall link between HT use and glioma risk. Further research is needed to confirm these results.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using machine learning models to identify severe subjective cognitive decline and related factors in nurses during the menopause transition: a pilot study.","authors":"Xiangyu Zhao, Xiaona Shen, Fengcai Jia, Xudong He, Di Zhao, Ping Li","doi":"10.1097/GME.0000000000002500","DOIUrl":"https://doi.org/10.1097/GME.0000000000002500","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to develop and validate a machine learning model for identifying individuals within the nursing population experiencing severe subjective cognitive decline (SCD) during the menopause transition, along with their associated factors.</p><p><strong>Methods: </strong>A secondary analysis was performed using cross-sectional data from 1,264 nurses undergoing the menopause transition. The data set was randomly split into training (75%) and validation sets (25%), with the Bortua algorithm employed for feature selection. Seven machine learning models were constructed and optimized. Model performance was assessed using area under the receiver operating characteristic curve, accuracy, sensitivity, specificity, and F1 score. Shapley Additive Explanations analysis was used to elucidate the weights and characteristics of various factors associated with severe SCD.</p><p><strong>Results: </strong>The average SCD score among nurses in the menopause transition was (5.38 ± 2.43). The Bortua algorithm identified 13 significant feature factors. Among the seven models, the support vector machine exhibited the best overall performance, achieving an area under the receiver operating characteristic curve of 0.846, accuracy of 0.789, sensitivity of 0.753, specificity of 0.802, and an F1 score of 0.658. The two variables most strongly associated with SCD were menopausal symptoms and the stage of menopause.</p><p><strong>Conclusions: </strong>The machine learning models effectively identify individuals with severe SCD and the related factors associated with severe SCD in nurses during the menopause transition. These findings offer valuable insights for the management of cognitive health in women undergoing the menopause transition.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of urinary tract infections in women with vulvovaginal atrophy and the impact of vaginal prasterone on the rate of urinary tract infections.","authors":"Rachel Rubin, May Sanaee, Alyssa Yee, Erick Moyneur, Katherine Dea, Alain Y Dury","doi":"10.1097/GME.0000000000002485","DOIUrl":"https://doi.org/10.1097/GME.0000000000002485","url":null,"abstract":"<p><strong>Objective: </strong>The aims of this study were to assess the prevalence of urinary tract infections (UTI) in women newly diagnosed with vulvovaginal atrophy (VVA) versus women without VVA and to evaluate the potential of vaginal prasterone to be used in postmenopausal VVA women with UTI as prophylaxis to reduce the future UTI risk. As a first subgroup analysis, women using aromatase inhibitors, medications that stop the production of estrogen were analyzed. As a second subgroup analysis, we looked at women with diabetes to investigate whether the same prophylaxis approach should be considered.</p><p><strong>Methods: </strong>This observational retrospective inception cohort study was conducted using the Integrated Dataverse open-source claims database with data from February 2015 through January 2020.</p><p><strong>Results: </strong>A total of 22,245 women treated with prasterone for a minimum of 12 weeks were matched to women without any prescribed VVA-related treatment. Overall, women treated with prasterone have a significantly lower UTI prevalence compared to those untreated (6.58% vs 12.3%; P < 0.0001). The highest difference in UTI prevalence among the prasterone treated and untreated women was observed in those aged 65-74 (7.15% vs 16.2%; P < 0.0001). Among aromatase inhibitor users and women with diabetes, those treated with prasterone have a significantly lower UTI prevalence (4.90% vs 9.79%; P < 0.01 and 14.59% vs 20.48%; P < 0.0001, respectively).</p><p><strong>Conclusions: </strong>This study suggests that intravaginal prasterone may be a good candidate for prophylaxis in postmenopausal women with UTI to reduce future UTI risk, including for women taking aromatase inhibitors and women with diabetes. This study is based on real-world evidence and warrants further investigation in a clinical setting.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142951026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fragmented QRS complexes in electrocardiogram and their relationship with somatic symptoms in postmenopausal women.","authors":"Busra Korpe, Caner Kose, Nazlı Turan Serifler, Vakkas Korkmaz, Huseyin Levent Keskin","doi":"10.1097/GME.0000000000002491","DOIUrl":"https://doi.org/10.1097/GME.0000000000002491","url":null,"abstract":"<p><strong>Objective: </strong>Menopause significantly impacts cardiovascular health, yet the relationship between myocardial abnormalities and noncardiac symptoms in postmenopausal women remains underexplored. This study aims to investigate the association between fragmented QRS waves (fQRS) positivity on electrocardiograms (ECG) and somatic symptoms in postmenopausal women.</p><p><strong>Methods: </strong>We included 623 postmenopausal women attending a menopause clinic for routine annual gynecological examinations. Women were categorized into fQRS-positive (n = 248) and fQRS-negative (n = 375) groups based on ECG results analyzed by a blinded cardiologist. The Menopause Rating Scale (MRS) was used to assess menopausal symptoms across three subscales: somatic, psychological, and urogenital. Data on demographics, physical activity, and medical history were also collected. Statistical analyses included comparisons of MRS scores, and a binary logistic regression analysis was used to identify the relationship between fQRS positivity and somatic symptoms. Adjusted models were created for potential confounders.</p><p><strong>Results: </strong>Women with fQRS positivity reported significantly higher somatic symptoms and total MRS scores compared to those without fQRS positivity. Specifically, higher scores were observed in the fQRS-positive group for the somatic subscale and total MRS score. Binary logistic regression analysis revealed that fQRS positivity was significantly associated with somatic symptoms after adjusting for all confounders (odds ratio, 10.76; 95% CI, 7.21-16.07; P < 0.001).</p><p><strong>Conclusions: </strong>Postmenopausal women with fQRS positivity on ECG exhibit a higher severity of somatic symptoms compared to those without fQRS positivity. These findings suggest a potential link between somatic symptoms and myocardial conduction abnormalities indicated by fQRS positivity. Further research is needed to clarify the underlying mechanisms of this association.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trauma history and persistent poor objective and subjective sleep quality among midlife women.","authors":"Karen Jakubowski, Carly A Riedmann, Yuefang Chang, Karestan C Koenen, Pauline M Maki, Rebecca C Thurston","doi":"10.1097/GME.0000000000002480","DOIUrl":"https://doi.org/10.1097/GME.0000000000002480","url":null,"abstract":"<p><strong>Objectives: </strong>Whereas some work links trauma exposure to poor subjective sleep quality, studies largely rely upon limited trauma measures and self-reported sleep at one time point. It is unknown whether trauma is related to persistent poor sleep, whether associations differ based on childhood versus adulthood trauma, and whether trauma exposure is related to poorer objectively assessed sleep. We tested whether childhood or adult trauma associated with persistent poor objectively and subjectively measured sleep at two time points in midlife women.</p><p><strong>Methods: </strong>One hundred sixty-seven women aged 40-60 at baseline were assessed twice 5 years apart. At baseline, women reported childhood trauma (Child Trauma Questionnaire), adult trauma (Brief Trauma Questionnaire), demographics, depressive symptoms, apnea symptoms, and medical history, and provided physical measures. At both visits, women completed 3 days of actigraphy (total sleep time [TST], wake after sleep onset [WASO]) and reported sleep quality (Pittsburgh Sleep Quality Index). Relations of childhood and adult trauma exposure, respectively, with persistent poor sleep at both baseline and follow-up visits (TST [<6 hours], WASO [>30 minutes], Pittsburgh Sleep Quality Index [>5]) were assessed in logistic regression models, adjusted for age, race/ethnicity, education, body mass index, sleep medications, nightshift work, apnea, depressive symptoms, vasomotor symptoms, and alcohol use.</p><p><strong>Results: </strong>Childhood trauma was related to persistent high WASO (odds ratio [95% confidence interval] = 2.16 [1.04-4.50], P = 0.039, multivariable). Adult trauma was related to persistent poor sleep quality (odds ratio [95% confidence interval] = 2.29 [1.07-4.93], P = 0.034, multivariable). Trauma was unrelated to persistent short TST.</p><p><strong>Conclusions: </strong>Childhood and adult trauma, respectively, were related to persistent poor objective sleep continuity and subjective sleep quality in midlife women, independent of risk factors.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142951226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microablative radiofrequency versus sham for overactive bladder: a randomized controlled trial.","authors":"Helena Slongo, Anna Lygia B Lunardi, Juliana C Fazzolari, Constanza D A Pérez, Cássio L Z Riccetto, Cássia R T Juliato","doi":"10.1097/GME.0000000000002492","DOIUrl":"https://doi.org/10.1097/GME.0000000000002492","url":null,"abstract":"<p><strong>Objective: </strong>Energy therapies have been suggested as potential treatments for overactive bladder (OAB), yet there are few studies examining their efficacy. This study aimed to compare the effects of fractional microablative radiofrequency (RF) to sham treatment.</p><p><strong>Methods: </strong>A pilot clinical trial was conducted with 77 women diagnosed with OAB, randomized into two groups: one receiving three monthly sessions of fractional microablative RF and the other receiving sham treatment, both combined with behavioral therapy. Assessments were conducted at baseline and 30 days after therapy using validated questionnaires for urinary symptoms (International Consultation on Incontinence Questionnaire-Short Form, Overactive Bladder, and Quality of Life), as well as vaginal and sexual function, and pelvic floor muscle functionality.</p><p><strong>Results: </strong>Both treatment groups demonstrated significant improvements in all validated questionnaires assessing urinary and vaginal symptoms (P < 0.001), with no significant differences between them. The International Consultation on Incontinence Questionnaire-Overactive Bladder scores improved significantly in both the RF group (-4.5 points; P < 0.001) and the sham group (-4.5 points; P < 0.001), with no significant differences between the groups (P = 0.812). Additionally, there were no improvements noted in sexual function or vaginal trophism in the RF group. However, assessments of endurance, resistance, and fast contractions of the pelvic floor muscles showed improvement only in the RF group, with no changes observed in power or perineometer measurements.</p><p><strong>Conclusions: </strong>Microablative RF treatment combined with behavioral therapy did not show benefits over sham treatment with behavioral therapy for addressing OAB symptoms.</p>","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}